Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

8 Nov 2021

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several variants have shown decreased...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34815117
DOI: 10.1016/j.vaccine.2021.11.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in micePMID 34815117Read ↗

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in miceSemantic proximity Read ↗

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strainsSemantic proximity Read ↗

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strainsSemantic proximity Read ↗

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.Semantic proximity Read ↗

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studiesSemantic proximity Read ↗

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine BoosterSemantic proximity Read ↗

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal modelsSemantic proximity Read ↗

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read ↗

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 VariantsSemantic proximity Read ↗

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2Semantic proximity Read ↗

Serum Neutralizing Activity of mRNA-1273 Against the SARS-CoV-2 B.1.1.529 (Omicron) Variant: A Preliminary ReportSemantic proximity Read ↗

mRNA-1273 and Ad26.COV2.S Vaccines Protect Against the B.1.621 Variant of SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.